Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

YKL-40 as marker of severe lung disease in cystic fibrosis patients.

Leonardi S, Parisi GF, Capizzi A, Manti S, Cuppari C, Scuderi MG, Rotolo N, Lanzafame A, Musumeci M, Salpietro C.

J Cyst Fibros. 2016 Sep;15(5):583-6. doi: 10.1016/j.jcf.2015.12.020. Epub 2016 Jan 8.

2.

The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease.

Hector A, Kormann MS, Mack I, Latzin P, Casaulta C, Kieninger E, Zhou Z, Yildirim AÖ, Bohla A, Rieber N, Kappler M, Koller B, Eber E, Eickmeier O, Zielen S, Eickelberg O, Griese M, Mall MA, Hartl D.

PLoS One. 2011;6(9):e24399. doi: 10.1371/journal.pone.0024399. Epub 2011 Sep 20.

3.

Characterisation of asthma subgroups associated with circulating YKL-40 levels.

Gomez JL, Yan X, Holm CT, Grant N, Liu Q, Cohn L, Nezgovorova V, Meyers DA, Bleecker ER, Crisafi GM, Jarjour NN, Rogers L, Reibman J, Chupp GL; SARP Investigators.

Eur Respir J. 2017 Oct 12;50(4). pii: 1700800. doi: 10.1183/13993003.00800-2017. Print 2017 Oct.

4.

Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis.

Coriati A, Massé C, Ménard A, Bouvet GF, Berthiaume Y.

Inflammation. 2018 Oct;41(5):1631-1639. doi: 10.1007/s10753-018-0806-7.

PMID:
29804188
5.

Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease.

Fantino E, Gangell CL, Hartl D, Sly PD; AREST CF.

BMC Pulm Med. 2014 Feb 27;14:28. doi: 10.1186/1471-2466-14-28.

6.

Association between serum YKL-40 level and dysglycemia in cystic fibrosis.

Bouvet GF, Maignan M, Arslanian E, Coriati A, Rabasa-Lhoret R, Berthiaume Y.

Cytokine. 2015 Feb;71(2):296-301. doi: 10.1016/j.cyto.2014.10.017. Epub 2014 Dec 11.

PMID:
25497736
7.

Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.

Laguna TA, Williams CB, Brandy KR, Welchlin-Bradford C, Moen CE, Reilly CS, Wendt CH.

J Cyst Fibros. 2015 May;14(3):334-40. doi: 10.1016/j.jcf.2014.10.002. Epub 2014 Oct 23.

8.

Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease.

James AJ, Reinius LE, Verhoek M, Gomes A, Kupczyk M, Hammar U, Ono J, Ohta S, Izuhara K, Bel E, Kere J, Söderhäll C, Dahlén B, Boot RG, Dahlén SE; BIOAIR (Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease) Consortium.

Am J Respir Crit Care Med. 2016 Jan 15;193(2):131-42. doi: 10.1164/rccm.201504-0760OC.

PMID:
26372680
9.

Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection.

Chirico V, Lacquaniti A, Leonardi S, Grasso L, Rotolo N, Romano C, Di Dio G, Lionetti E, David A, Arrigo T, Salpietro C, La Rosa M.

Clin Microbiol Infect. 2015 Apr;21(4):368.e1-9. doi: 10.1016/j.cmi.2014.11.004. Epub 2014 Nov 15.

10.

Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.

Laguna TA, Wagner BD, Luckey HK, Mann SA, Sagel SD, Regelmann W, Accurso FJ.

Chest. 2009 Dec;136(6):1561-1568. doi: 10.1378/chest.09-0217. Epub 2009 Jun 30.

11.

Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.

Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Goss CH.

Contemp Clin Trials. 2013 Nov;36(2):460-9. doi: 10.1016/j.cct.2013.09.004. Epub 2013 Sep 19.

12.

Identification of neutrophil activation markers as novel surrogate markers of CF lung disease.

Rath T, Zwaschka L, Hage L, Kügler M, Menendez K, Naehrlich L, Schulz R, Roderfeld M, Roeb E.

PLoS One. 2014 Dec 29;9(12):e115847. doi: 10.1371/journal.pone.0115847. eCollection 2014.

13.

Serum YKL-40 levels may help distinguish exacerbation of post-infectious bronchiolitis obliterans from acute bronchiolitis in young children.

Jang YY, Park HJ, Chung HL.

Eur J Pediatr. 2017 Jul;176(7):971-978. doi: 10.1007/s00431-017-2940-x. Epub 2017 Jun 1.

PMID:
28567534
15.

High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.

Nordenbaek C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, Price PA, Jacobsen S.

Scand J Rheumatol. 2005 Jul-Aug;34(4):293-7.

PMID:
16195162
16.

The relationship between serum YKL-40 levels and arterial stiffness in patients with ankylosing spondylitis.

Kucukali Turkyilmaz A, Devrimsel G, Serdaroglu Beyazal M, Kirbas A, Cicek Y, Capkin E, Karkucak M, Gokmen F.

Acta Reumatol Port. 2017 Apr-Jun;42(2):183-190.

17.

Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.

Reid DW, Misso N, Aggarwal S, Thompson PJ, Walters EH.

Respirology. 2007 Jan;12(1):63-9.

PMID:
17207027
18.

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Bonella F, Long X, He X, Ohshimo S, Griese M, Guzman J, Costabel U.

Respirology. 2017 Oct;22(7):1371-1378. doi: 10.1111/resp.13082. Epub 2017 May 31.

19.

Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis.

Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, Hayakawa H, Kusagaya H, Nakano Y, Nakamura H, Chida K.

Respir Med. 2010 Aug;104(8):1204-10. doi: 10.1016/j.rmed.2010.02.026. Epub 2010 Mar 27.

20.

Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.

Hozumi H, Fujisawa T, Enomoto N, Nakashima R, Enomoto Y, Suzuki Y, Kono M, Karayama M, Furuhashi K, Murakami A, Inui N, Nakamura Y, Mimori T, Suda T.

J Rheumatol. 2017 Sep;44(9):1394-1401. doi: 10.3899/jrheum.170373. Epub 2017 Jul 15.

PMID:
28711881

Supplemental Content

Support Center